antineoplastic agent protein kinase inhibitor afatinib (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide 2024-01-15T13:43:35Z CHEBI:61390 CID:10184653 This is any condition in which the main influencing factor is afatinib, an inhibitor of epidermal growth factor receptor (EGFR, ERBB2, ERBB3, ERBB4) tyrosine kinases used for the treatment of metastatic non-small cell lung cancer. XCO:0001240 experimental_condition_ontology slaulederkind